Dasatinib therapy was discontinued during admission and bosutinib therapy, an alternative BCR-ABL tyrosine kinase inhibitor, was initiated for the management of the patient’s CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.